| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Jen Liu, Juliana Chang, Po-Huang Lee, Deng-Yn Lin, Cheng-Chung Wu, Long-Bin Jeng, Yih-Jyh Lin, King-Tong Mok, Wei-Chen Lee, Hong-Zen Yeh, Ming-Chih Ho, Sheng-Shun Yang, Mei-Due Yang, Ming-Chin Yu, Rey-Heng Hu, Cheng-Yuan Peng, Kuan-Lang Lai, Stanley Shi-Chung Chang and Pei-Jer Chen |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| NIH Clinical Trial Registration |
NCT00247728 (to Chen PJ, Lai KL and Chang SSC) |
| Taiwan Liver Disease Consortium, the National Research Program for Biopharmaceuticals, and the National Science Council, Taiwan |
NSC100-2325-B-002-052 |
| Taiwan Liver Disease Consortium, the National Research Program for Biopharmaceuticals, and the National Science Council, Taiwan |
NSC102-2325-B-002-079 |
|
| Corresponding Author |
Correspondence to: Pei-Jer Chen, MD, PhD, Distinguished Professor, Graduate Institute of Clinical Medicine, Hepatitis Research Center and Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, 1 Chang-Te Street, Taipei 10002, Taiwan. peijerchen@ntu.edu.tw |
| Key Words |
Antiangiogenesis; Antimetastasis; Adjuvant therapy; Disease-free survival; Heparanase inhibitor; Hepatocellular carcinoma; PI-88; Tumor recurrence |
| Core Tip |
A phase Ⅱ clinical trial demonstrated that heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to one year following curative resection. This observational follow-up study extended the follow-up period to 3 years. A total of 143 patients participated in the study. PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment. Subgroup analyses revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage for patients at high risk of recurrence. |
| Publish Date |
2014-08-29 11:57 |
| Citation |
Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SSC, Chen PJ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(32): 11384-11393 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i32/11384.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i32.11384 |
